Actinium Pharma Announces Research Collaboration With Astellas
Actinium Pharma Announces Research Collaboration With Astellas TOKYO (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) announced the research collaboration with Astellas Pharma Inc. (ALPMY, ALPMY) to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform. Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225. Actinium's AWE technology patent portfolio includes 30 patent families comprised of over 135 issued or pending global patent appli...
Source: finanznachrichten.de